[3] Ronald P. Taylor, a professor of biochemistry and molecular genetics at the University of Virginia developed protein complexes called heteropolymers that mimic the natural process of white and red blood cells in clearing out the disease off the bloodstream.
Wolf also arranged to have Elusys' board of directors made up of people with prior experience from top global pharmaceutical companies and Food and Drug Administration (FDA).
Elusys initially collaborated with University of Texas at Austin and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in the development of Anthim.
In 2011, the company was awarded with an additional five-year contract valued at $68.9 million to develop intramuscular injection for anthrax prevention measure.
[13] In November 2015, the company received a five-year contract of $44.9 million for the production and future delivery of Anthim to the Strategic National Stockpile.